September 5, 2017
Ottawa, September 28, 2017 The following statement can be attributed to Innovative Medicines Canada’s president, Pamela Fralick: “Innovative Medicines Canada and its member companies are proud to be an integral […]
Ottawa, September 27, 2017 The following statement can be attributed to Innovative Medicines Canada’s president, Pamela Fralick: “The innovative pharmaceutical industry will review any proposed legislation with respect to disclosure […]
Ottawa, September 21, 2017 With regards to the provisional application of the Comprehensive and Economic Trade Agreement (CETA), Pamela Fralick, President, Innovative Medicines Canada issued the following statement: “Innovative Medicines […]
Ottawa, September 11, 2017 The following statement can be attributed to Innovative Medicines Canada’s president, Pamela Fralick: “Innovative Medicines Canada is supportive of the actions the federal government is taking […]
Ottawa, September 7, 2017 The following statement can be attributed to Pamela Fralick, President, Innovative Medicines Canada. “Innovative Medicines Canada (IMC) has supported the Comprehensive and Economic Trade Agreement (CETA) […]
